<DOC>
	<DOCNO>NCT02405338</DOCNO>
	<brief_summary>This multi-centre , open label , prospective , non-randomized phase I/II trial 20 patient include safety-run phase I part comprise 6 patient . Trial subject receive repeat immunotherapy autologous Dendritic Cells ( DCs ) , present two leukemia-associated antigen .</brief_summary>
	<brief_title>DC Vaccination Post-remission Therapy AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis Acute Myeloid Leukemia ( AML ) Age 18 75 year Morphologic remission ( CR ) without hematological recovery ( CRi ) follow induction chemotherapy WT1 without PRAME positivity qPCR Negative pregnancy test woman childbearing potential ( within 7 day first vaccination ) . Women childbearing potential sexually active male participant must use reliable method contraception whole treatment period 3 month last trial drug dose Negative HIV 1 2 test , Hepatitis B C test negative Syphilis test screening Informed consent sign prior trial related activity Patients suitable allogeneic stem cell transplantation AML M3 ( acute promyelocytic leukemia ) Patients complete remission ( CR CRi ) , bone marrow blast count â‰¥ 5 % Active immunodeficiency syndrome Concurrent active second malignancy nonmelanoma skin cancer Clinically relevant autoimmune disease Prior immunotherapy Severe organ dysfunction preclude apheresis procedure : Creatinine &gt; 200 mmol/l Bilirubin , ALAT ASAT &gt; 3 x upper normal limit Respiratory insufficiency pO2 &lt; 60 mmHg Clinically relevant coronary heart disease ventricular arrhythmia , congestive heart failure &gt; grade II NYHA Recent cerebral hemorrhage Known allergy substance use generation DCs Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate trial participation administration investigational product Use corticosteroid Active CMV infection ( Antibodypositivity due previous , inactive infection accept ) Inability comply trial protocol Participation clinical trial , accord investigator 's discretion , may interfere trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>AML</keyword>
</DOC>